Dynavax Technologies Azioni (NASDAQ: DVAX)

Ultime notizie per Dynavax Technologies (NASDAQ:DVAX) Azioni

Dynavax Technologies

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

<p>HC Wainwright &amp; Co.  analyst Edward White   maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and raises the price target from $29 to $31.</p>


News

Price Target

Analyst Ratings

DVAX

HC Wainwright & Co. Maintains Buy on Dynavax Technologies, Raises Price Target to $31

Guidance

Dynavax Prelim. 2024 HEPLISAV-B Net Product Revenue Grew 26% YoY To $268M

Buybacks

Dynavax Announces $100M Accelerated Share Repurchase Program Under Agreement With Goldman Sachs

WIIM

Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.

<p>HC Wainwright &amp; Co.  analyst Edward White   reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $29 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.11 by 9.09 percent.  The company reported quarterly sales of $80.630 million which missed the analyst consensus estimate of $84.166 million by 4.20 percent.  This is a 15.99 percent increase over sales of $69.514 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Dynavax Technologies Q3 2024 GAAP EPS $0.12 Beats $0.11 Estimate, Sales $80.630M Miss $84.166M Estimate

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) will release its quarterly earnings report on Thursday, 2024-11-07. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Dynavax Technologies to report an <strong>earnings per share</strong> (EPS) of $0.11.</p>
<p>The announcement from Dynavax Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 6.97% increase in the share price the following trading session.</p>
<p>Here's a look at Dynavax Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.08</td>
<td>-0.07</td>
<td>0</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730919682_0.png" alt="eps graph" /></p>
<h3>Performance of Dynavax Technologies Shares</h3>
<p>Shares of Dynavax Technologies were trading at $12.01 as of November 05. Over the last 52-week period, shares are down 6.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Dynavax Technologies</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Dynavax Technologies.</p>
<p>The consensus rating for Dynavax Technologies is Buy, based on 2 analyst ratings. With an average one-year price target of $22.0, there's a potential 83.18% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Myriad Genetics and Kiniksa Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus among analysts is an Neutral trajectory for Myriad Genetics, with an average 1-year price target of $32.75, indicating a potential 172.69% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Kiniksa Pharmaceuticals, with an average 1-year price target of $38.33, indicating a potential 219.15% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Myriad Genetics and Kiniksa Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynavax Technologies</td>
<td>Buy</td>
<td>22.48%</td>
<td>$61.81M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Neutral</td>
<td>15.26%</td>
<td>$147.10M</td>
<td>-4.89%</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Outperform</td>
<td>67.37%</td>
<td>$62.80M</td>
<td>-2.91%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Dynavax Technologies ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Dynavax Technologies is at the bottom compared to its peers.</p>
<h3>Delving into Dynavax Technologies's Background</h3>
<p>Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.</p>
<h3>Breaking Down Dynavax Technologies's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Dynavax Technologies showcased positive performance, achieving a revenue growth rate of <strong>22.48%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Dynavax Technologies's net margin is impressive, surpassing industry averages. With a net margin of <strong>15.43%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.81%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Dynavax Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.14%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.39</strong>, Dynavax Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/DVAX/earnings"><strong>To track all earnings releases for Dynavax Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Dynavax Technologies's Upcoming Earnings

<p>Dynavax Technologies Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>), a commercial-stage biopharmaceutical company developing and&nbsp;commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan").</p>
<p>The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing its ownership of 13.6% of the Company's outstanding common stock. The Rights Plan is intended to protect the investment of Dynavax stockholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential. The Rights Plan should reduce the likelihood that any person or group gains control of Dynavax through open market accumulation without paying all stockholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders.</p>
<p>The Rights Plan, which is similar to other plans adopted by publicly held companies, does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights. The Rights Plan does not limit the Board's ability to engage in discussions or pursue transactions it believes are in the best interests of all stockholders.</p>


Management

Dynavax Adopts Limited-Duration Stockholder Rights Plan, Effective Immediately

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.5, a high estimate of $29.00, and a low estimate of $15.00. This current average represents a 4.67% decrease from the previous average price target of $26.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723132810_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Dynavax Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dynavax Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Dynavax Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dynavax Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dynavax Technologies analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Dynavax Technologies</h2>
<p>Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.</p>
<h3>Dynavax Technologies: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Dynavax Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>22.48%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dynavax Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>15.43%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Dynavax Technologies's ROE excels beyond industry benchmarks, reaching <strong>1.81%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dynavax Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.14%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Dynavax Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.39</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Dynavax Technologies: Insights From 4 Financial Analysts

<p>Goldman Sachs  analyst Paul Choi   maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Neutral and lowers the price target from $20 to $15.</p>


Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15

Dynavax Reaffirms 2024 HEPLISAV-B Net Product Revenue Guidance Of $265M-$280M

<p>Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year.  The company reported quarterly sales of $73.795 million which missed the analyst consensus estimate of $76.102 million by 3.03 percent.  This is a 22.48 percent increase over sales of $60.249 million the same period last year.</p>


Dynavax Technologies Q2 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $73.795M Miss $76.102M Estimate

Dynavax Reappoints Kelly MacDonald As CFO Effective August 1, 2024; Ryan Spencer Continues As CEO After Serving As Interim CFO During MacDonald's Maternity Leave; No Change In MacDonald's Compensation

Biotech

General

Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018

<p>Tuesday,&nbsp;<strong>Dynavax Technologies Corporation</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>)&nbsp;provided a regulatory update for its supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis.&nbsp;</p>
<p>The FDA has issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose regimen of HEPLISAV-B.&nbsp;</p>
<p>The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union, and&nbsp;Great Britain, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18&nbsp;years of age&nbsp;and older.&nbsp;</p>
<p>The CRL also does not affect the approval decision&nbsp;received from&nbsp;the European Commission in&nbsp;October 2023&nbsp;for the four-dose HEPLISAV-B&nbsp;regimen for the adult hemodialysis population.</p>
<p>The supplemental application included clinical immunogenicity and safety data from the Phase 1 HBV-24 study of a four-dose regimen of HEPLISAV-B in 119 adults undergoing hemodialysis, as well as five supportive clinical trials of HEPLISAV-B in adults with chronic kidney disease or undergoing hemodialysis.&nbsp;</p>
<p>The CRL stated that the data from HBV-24&nbsp;were insufficient&nbsp;due to the destruction of data source documents by a third-party clinical trial site operator for approximately half of the subjects enrolled in the trial.&nbsp;</p>
<p>In addition, the total number of subjects in the single-arm HBV-24 study&nbsp;was&nbsp;deemed&nbsp;insufficient&nbsp;to evaluate the four-dose regimen&#8217;s safety.</p>
<p>&#8220;We are reviewing the agency&#8217;s feedback and intend to request a meeting with the FDA to evaluate options for providing additional data to support the four-dose regimen for this vulnerable patient population in the U.S.,&#8221; said&nbsp;Rob Janssen,&nbsp;Dynavax&#8217;s Chief Medical Officer.</p>
<p>In&nbsp;first quarter&nbsp;2024,&nbsp;HEPLISAV-B vaccine&nbsp;achieved net product revenue of&nbsp;$47.8 million&nbsp;up from&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38711968/dynavax-reports-first-quarter-2024-financial-results-and-provides-business-updates" rel="noreferrer noopener">$43.5 million&nbsp;a year ago</a>.</p>
<p>HEPLISAV-B&nbsp;total estimated market share in the U.S. increased to approximately 41%, compared to approximately 37% at the end of the first quarter&nbsp;2023.</p>
<p><strong>Price Action:</strong>&nbsp;At last check on Tuesday, DVAX shares were down 1.36% at $10.88.</p>


Health Care

Movers

Trading Ideas

FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients

Dynavax enters $100M accelerated share repurchase agreement

Dynavax Technologies: What The Stock Buyback Means.  What It Doesn't

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the f...

Dynavax sees Q4 HEPLISAV-B revenue $71M

HEPLISAV-B achieved preliminary net product revenue of $268M for the full year 2024, an increase of 26% compared to $213M for the full year 2023. F...

Dynavax sees FY24 HEPLISAV-B revenue $268M

Dynavax Technologies guides Q4 and FY topline figures

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $29.00. The company...

Dynavax (DVAX) Receives a Buy from JMP Securities

Analyst Phil Nadeau of TD Cowen maintained a Buy rating on Dynavax (DVAX – Research Report), retaining the price target of $25.00. Phil Nadeau has ...

Strong Market Position and Growth Potential Drive Buy Rating for Dynavax

H.C. Wainwright analyst Edward White has reiterated their bullish stance on DVAX stock, giving a Buy rating yesterday. Edward White's rating is bas...

Dynavax's Strong Growth Potential Driven by Heplisav-B Sales and Strategic Market Positioning

H.C. Wainwright raised the firm's price target on Dynavax (DVAX) to $31 from $29 and keeps a Buy rating on the shares. The company's preliminary Q4...

Comments

Dynavax Technologies

Notizie

Ultime notizie per Dynavax Technologies (NASDAQ:DVAX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO